U.S. puts Canada on watch list over drug-patent policy

05/7/2013 | Financial Post (Canada)

The Office of the U.S. Trade Representative expressed concern over Canada's treatment of pharmaceutical patents in a newly issued report on intellectual-property issues. The trade office placed Canada on its watch list for issues relating to the lack of appeal rights for innovative companies and heightened utility requirements that may violate trade agreements.

View Full Article in:

Financial Post (Canada)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX